Trust Co. of Vermont Has $33.01 Million Stock Holdings in Johnson & Johnson $JNJ

Trust Co. of Vermont lifted its position in shares of Johnson & Johnson (NYSE:JNJ) by 3.0% in the third quarter, Holdings Channel reports. The institutional investor owned 178,024 shares of the company’s stock after acquiring an additional 5,241 shares during the period. Johnson & Johnson makes up about 1.4% of Trust Co. of Vermont’s portfolio, making the stock its 13th largest position. Trust Co. of Vermont’s holdings in Johnson & Johnson were worth $33,009,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Lifestyle Asset Management Inc. raised its stake in Johnson & Johnson by 3.4% in the 3rd quarter. Lifestyle Asset Management Inc. now owns 1,683 shares of the company’s stock worth $312,000 after purchasing an additional 56 shares in the last quarter. Wynn Capital LLC increased its holdings in shares of Johnson & Johnson by 0.4% during the third quarter. Wynn Capital LLC now owns 15,930 shares of the company’s stock worth $2,954,000 after purchasing an additional 57 shares during the period. W.H. Cornerstone Investments Inc. raised its position in shares of Johnson & Johnson by 0.7% in the second quarter. W.H. Cornerstone Investments Inc. now owns 7,896 shares of the company’s stock valued at $1,206,000 after buying an additional 58 shares in the last quarter. YANKCOM Partnership boosted its stake in shares of Johnson & Johnson by 0.8% in the second quarter. YANKCOM Partnership now owns 7,042 shares of the company’s stock valued at $1,076,000 after buying an additional 58 shares during the period. Finally, Greenup Street Wealth Management LLC grew its position in Johnson & Johnson by 3.1% during the second quarter. Greenup Street Wealth Management LLC now owns 2,021 shares of the company’s stock worth $309,000 after buying an additional 60 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Key Stores Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: EU approval for Tremfya in pediatric plaque psoriasis expands JNJ’s commercial opportunity in immunology and makes Tremfya the first IL?23 inhibitor cleared for any pediatric indication — a potential revenue tailwind. JNJ’s Tremfya Gets EU Approval for Pediatric Plaque Psoriasis
• Positive Sentiment: FDA cleared a subcutaneous formulation of Rybrevant for NSCLC, improving patient convenience and potentially broadening uptake versus IV; this strengthens oncology growth prospects. J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant (Revised)
• Positive Sentiment: Multiple analyst pieces and model portfolios continue to flag JNJ as a high?yield, defensive stock for 2026 — supporting demand from income and conservative equity investors. Top 5 High-Yield S&P 500 Stocks to Buy for Reliable Returns in 2026
• Neutral Sentiment: Stifel Nicolaus reiterated a Hold rating on JNJ — a reminder that some analysts remain cautious on near?term upside despite pipeline progress. Stifel Nicolaus Reaffirms Their Hold Rating on Johnson & Johnson (JNJ)
• Neutral Sentiment: Market commentary and earnings previews highlight stronger Q3 results and recent rally/valuation debates — these narratives help explain interest in the stock but don’t change fundamentals immediately. Here’s Why Johnson & Johnson (JNJ) Surged in Q3
• Negative Sentiment: A Baltimore jury ordered J&J to pay roughly $1.5B in a talc/asbestos mesothelioma case — the largest single?plaintiff talc award reported — creating legal liability risk, potential settlement/appeal costs, and headline volatility. J&J vows appeal after US jury hits it with record $1.5 billion talc cancer award
• Negative Sentiment: Company statements and multiple outlets report the verdict and ongoing exposure (tens of thousands of talc suits), which could weigh on sentiment, raise legal reserves or influence long?term liability assumptions. Over $1.5 Billion Baltimore Verdict Holds Johnson & Johnson Liable Over Iconic Baby Powder

Johnson & Johnson Trading Up 1.1%

Shares of Johnson & Johnson stock opened at $208.01 on Thursday. The firm’s 50 day moving average is $199.06 and its 200 day moving average is $180.31. The firm has a market capitalization of $501.14 billion, a PE ratio of 20.08, a price-to-earnings-growth ratio of 2.23 and a beta of 0.36. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $215.18. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th were issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend was Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is presently 50.19%.

Analysts Set New Price Targets

Several analysts have recently issued reports on the company. Loop Capital set a $190.00 target price on Johnson & Johnson in a report on Wednesday, October 22nd. Daiwa America upgraded shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. Wells Fargo & Company boosted their target price on shares of Johnson & Johnson from $212.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, December 12th. Royal Bank Of Canada set a $240.00 price target on shares of Johnson & Johnson in a research report on Wednesday, December 17th. Finally, Daiwa Capital Markets upgraded shares of Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price objective for the company in a research report on Monday, October 20th. Four research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $210.25.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.